Evogene Chief Development Officer Gabi Tarcic acquires 1,129 shares for $677.40
EVGN•Options disclosure
Disclosure also lists 40,000 stock options with an exercise price of USD 2.31.
Chief Development Officer buys ordinary shares
Evogene Chief Development Officer Gabi Tarcic bought 1,129 ordinary shares at USD 0.6 each.
Direct holding rose to 1,129 ordinary shares.
